Preclinical pharmacology of zoledronic acid

被引：26

作者：

Green, JR ^{[1
]}

机构：

[1] Novartis Pharma AG, CH-4002 Basel, Switzerland

来源：

SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 06期

关键词：

D O I：

10.1053/sonc.2002.37421

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / 11

页数：9

共 57 条

[1] Alendronate disturbs vesicular trafficking in osteoclasts [J].

Alakangas, A ;

Selander, K ;

Mulari, M ;

Halleen, J ;

Lehenkari, P ;

Mönkkönen, J ;

Salo, J ;

Väänänen, K .

CALCIFIED TISSUE INTERNATIONAL, 2002, 70 (01) :40-47

[2]

BARE S, 1997, J BONE MINER RES S1, V12, pS473

[3] Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro [J].

Benford, HL ;

McGowan, NWA ;

Helfrich, MH ;

Nuttall, ME ;

Rogers, MJ .

BONE, 2001, 28 (05) :465-473

[4]

Berenson JR, 2001, CANCER, V91, P144, DOI 10.1002/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO

[5]

2-Q

[6]

Berenson JR, 2001, CLIN CANCER RES, V7, P478

[7]

Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO

[8]

2-0

[9] Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys [J].

Binkley, N ;

Kimmel, D ;

Bruner, J ;

Haffa, A ;

Davidowitz, B ;

Meng, C ;

Schaffer, V ;

Green, J .

JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (11) :1775-1782

[10]

BOUNAMEAUX HM, 1983, LANCET, V1, P471

← 1 2 3 4 5 6 →